Reduced fluence rate PDT
View Patent ↗The invention relates to the use of reduced fluency rate PDT to treat neovasculature, particularly choroidal neovasculature (CNV). Reduced fluency rate PDT decreases the likelihood of molecular oxygen being the limiting factor in the photodynamic reaction so that the concentration of either photons (light intensity) or photosensitizer in the target tissue controls the photodynamic reaction.
1. A method for treating neovasculature or choroidal neovasculature (CNV) using photodynamic therapy (PDT), said method consisting essentially of:
administering a photosensitizer (PS) and
irradiating said photosensitizer (PS) proximate to the neovasculature or CNV of a human subject afflicted with said neovasculature or CNV with an amount of electromagnetic radiation containing a wavelength absorbed by said PS at a fluence rate which delivers a total light dose of from about 12.5 to about 25 J/cm 2 ,
wherein said fluence rate results in closure of CNV and decreases closure of normal choriocapillaris, and
wherein said PS is a green porphyrin.
2. The method of claim 1 , wherein said amount of electromagnetic radiation is an amount containing a wavelength absorbed by said PS which is less than an amount needed to activate all of the PS at a fluency rate of about 150-300 mW/cm 2 and wherein the PS is BPD-MA administered at a concentration of 6 mg/m 2 .
3. The method of claim 1 , wherein the choroidal neovasculature (CNV) is in a subject afflicted or diagnosed with age-related macular degeneration (AMD).
4. The method of claim 3 , wherein the AMD is the “wet” form.
5. The method of claim 1 , wherein the PS is formulated with a carrier.
6. The method of claim 5 , wherein the PS is formulated in a liposome, emulsion, or aqueous solution.
7. The method of claim 1 , wherein the PS is administered as a pharmaceutical composition.
8. The method of claim 1 , wherein the reduced fluency rate is about 150-300 mW/cm 2 .
9. The method of claim 8 , wherein the reduced fluency rate is 150 mW/cm 2 .
10. The method of claim 8 , wherein the reduced fluency rate is 300 mW/cm 2 .
11. The method of claim 1 , wherein the electromagnetic radiation contains wavelengths in the visible light spectra.
12. The method of claim 1 , wherein said irradiating occurs between 5 to 30 minutes after administration.
13. The method of claim 1 , wherein the PS is administered at a concentration ranging between about 2 to 8 mg/m 2 (PS/body surface area of subject).
14. The method of claim 13 , wherein the PS is administered at a concentration of 6 mg/m 2 .
15. The method of claim 1 , wherein the PS is administered at a concentration ranging between about 10 μg/kg to 100mg/kg (PS/body weight of subject).
16. The method of claim 1 , wherein the green porphyrin is selected from BPD-DA, BPD-DB, BPD-MA, BPD-MB, EA6, and B3.
17. The method of claim 16 , wherein the green porphyrin is BPD-MA.
18. A method for treating neovasculature or choroidal neovasculature (CNV) using photodynamic therapy (PDT), consisting essentially of:
administering a photosensitizer (PS) and
irradiating said photosensitizer (PS) proximate to the neovasculature or CNV of a human subject afflicted with said neovasculature or CNV with an amount of electromagnetic radiation containing a wavelength absorbed by said PS at a fluency rate of about 50 to less than 150 mW/cm 2 ,
wherein said fluence rate results in closure of CNV and decreases closure of normal choriocapillaris, and
wherein said PS is a green porphyrin.
19. The method of claim 18 , wherein the green porphyrin is BPD-MA administered at a concentration of 6 mg/m 2 .
20. The method of claim 8 , wherein the fluence rate is about 150 mW/cm 2 .
21. The method of claim 8 , wherein the reduced fluence rate is about 300 mW/cm 2 .
22. The method of claim 1 , wherein said irradiating occurs 15 minutes after the start of said administering.
23. The method of claim 18 , wherein said irradiating occurs 15 minutes after the start of said administering.